As a Free StocksGuide user, you can view scores for all 7,029 stocks worldwide.
6 Analysts have issued a Anebulo Pharmaceuticals Inc forecast:
6 Analysts have issued a Anebulo Pharmaceuticals Inc forecast:
| Jun '25 | 
    +/-
   
    %
   | ||
| Revenue | - - | 
    -
 | |
| Gross Profit | - - | 
    -
 | |
| EBITDA | - - | 
    -
 | |
| EBIT (Operating Income) EBIT | -9.22 -9.22 | 
      
        
        11%
      
      
        
        11%
      
 | |
| Net Profit | -8.48 -8.48 | 
      
        
        3%
      
      
        
        3%
      
 | |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Anebulo Pharmaceuticals, Inc. engages in the provision of pharmaceutical services. The firm product candidate is ANEB-001, a potent, small molecule cannabinoid receptor antagonist, designed to address the unmet medical need for a specific antidote for cannabinoid overdose. The company was founded by Lawyer Joseph F on April 23, 2020 and is headquartered in Lakeway, TX.
| Head office | United States | 
| CEO | Richard Cunningham | 
| Employees | 3 | 
| Founded | 2020 | 
| Website | www.anebulo.com | 
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


